51784-73-7

Basic information

• Product Name: 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE
• Synonyms: BUTTPARK 52\08-07;2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE;2-PIPERIDIN-4-YL-1,3-BENZOTHIAZOLE;2-PIPERIDIN-4-YL-BENZOTHIAZOLE;OTAVA-BB BB7020410142;Benzothiazole, 2-(4-piperidinyl)- (9CI);2-(4-piperidinyl)-1,3-benzothiazole (en);2-(Piperidin-4-yl)benzo[d]thiazole
• CAS NO: 51784-73-7
• Molecular Formula: C₁₂H₁₄N₂S
• Molecular Weight: 218.32
• Product Categories: BENZOTHIAZOLE
• Mol File: 51784-73-7.mol

Chemical Properties

• Boiling Point: 361.516 °C at 760 mmHg
• Flash Point: 172.439 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.68±0.10(Predicted)
• CAS DataBase Reference: 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE(51784-73-7)
• EPA Substance Registry System: 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE(51784-73-7)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 51784-73-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE is used as a building block or intermediate for the synthesis of various complex organic compounds. Its unique structure, which includes a benzothiazole and a piperidine ring, allows it to participate in a wide range of chemical reactions, making it a valuable component in the development of new molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE is used as a key component in the development of new pharmaceutical compounds. Its structure may contribute to the creation of novel drugs with improved therapeutic properties, such as increased efficacy, reduced side effects, or enhanced bioavailability. 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE's potential role in drug discovery is currently being explored, and further research is needed to fully understand its capabilities and limitations in this field.
Used in Material Science:
2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE is used as a component in the development of new materials with unique properties. Its incorporation into polymers, for example, may result in materials with improved mechanical strength, thermal stability, or electrical conductivity. 2-(4-PIPERIDINYL)-1,3-BENZOTHIAZOLE's potential applications in material science are diverse and may include the creation of advanced materials for use in electronics, aerospace, or other high-tech industries.

InChI:InChI=1/C12H14N2S/c1-2-4-11-10(3-1)14-12(15-11)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2

Upstream product

• 498-94-2 isonipecotic acid 
• 137-07-5 2-amino-benzenethiol 
• 951381-76-3 C₁₂H₁₅BrN₂O 
• 100-68-5 methyl-phenyl-thioether 
• 144-55-8 sodium hydrogencarbonate 
• 301220-11-1 1-(4-(benzo[d]thiazol-2-yl)piperidin-1-yl)ethanone 
• 1373879-28-7 tert-butyl 4-(benzo[d]thiazol-2-yl)piperidine-1-carboxylate 

Downstream Products

• 1026403-88-2 2-(1-{3-[2-(4-Fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperidin-4-yl)-benzothiazole 
• 301220-12-2 α-(R)-(3-(S)-((4-(benzothiazol-2-yl)piperidin-1-yl)methyl)-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid, 4-methoxybenzyl ester 
• 1596340-58-7 2-(1-(3-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)propyl)piperidin-4-yl)benzo[d]thiazole 
• 1596340-60-1 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]thiazole 
• 1596340-62-3 2-(1-(5-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)pentyl)piperidin-4-yl)benzo[d]thiazole 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION

In one aspect, the invention relates to substituted l-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1 -mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.

NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME

The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes composit

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

A novel practical synthesis of benzothiazoles via Pd-catalyzed thiol cross-coupling

A convenient synthesis of substituted benzothiazoles from 2-bromoanilides has been accomplished. The various 2-bromoanilides were reacted with an alkyl thiolate in high yields using a palladium catalyst. The resulting sulfides were easily converted to the corresponding benzothiazoles via the simultaneous generation of thiols and condensation under basic or acidic conditions.

Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry

A series of novel benzimidazoles were efficiently synthesized using both solution- and solid-phase chemistry. These compounds were found to bind to the bacterial 16S ribosomal RNA A-site with micromolar affinities using unique mass spectrometry-based assays.

PROLINE DERIVATIVES AND USE THEREOF AS DRUGS

The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Non-imidazole histamine H3 ligands, part 2: New 2-substituted benzothiazoles as histamine H3 antagonists

New, non-imidazole histamine H3 receptor antagonists were prepared and in vitro tested as H3 receptor antagonists measured as the electrically evoked contraction of the guinea-pig jejunum. The 2-(1-piperidinyl)- and 2- (1-pyrrolidinyl)benzothiazoles show no or very poor activity; 2-[1-(4- amino)piperidinyl]- and 2-(1,2-ethanediamino)- and (2-(1,3- propanediamino)derivatives of benzothiazole possess weak activity at H3 receptors, whereas 2-(4-piperidinyl)benzothiazoles and 2-[1-(4- piperazinyl)]benzothiazoles show moderate to good activity. Lipophilic and not-too-bulky substituents like n-propyl attached to the nitrogen at the piperazine or piperidine ring lead to potent H3 receptor antagonists with pA2 values ranging from 7.0 to 7.2. The structure-activity relationships for different substitution patterns are discussed.